Clinical trials: Sweat Gland Diseases
HYPERHIDROSIS
Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT01810991
- Testing
- Nd:YAG Laser
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cynosure, Inc.
Hidradenitis Suppurativa (HS)
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).
- Trial name
- NCT06241573
- Testing
- Spesolimab
- Where
- 36 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
- Trial name
- NCT02805595
- Testing
- 23.4% Hypertonic saline
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
Clinical and Biological Characteristics of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition.
- Trial name
- NCT03967600
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Fabry Disease
An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
This study will evaluate the safety of multiple biweekly intravenous doses of Replagal over 26 weeks in 25 children with Fabry disease and the way in which that agent can improve the health of this patient population.
- Trial name
- NCT00071877
- Testing
- Replagal
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Hidradenitis Suppurativa
Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa
This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on…
- Trial name
- NCT04600375
- Testing
- Verbal consultation, Written Action Plan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Psoriasis, Eczema/Atopic Dermatitis
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, atopic dermatitis (eczema) and hidradenitis suppurativa are long-term skin conditions that flare and settle over time. Most of what happens to the skin happens at home, between hospital appointments.
- Conditions
- Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS)
- Trial name
- Skin-in-Sight (NCT07804134)
- Where
- 3 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Medisch Spectrum Twente
Hidradenitis Suppurativa, Acne Inversa
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other…
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
- Trial name
- NCT04019041
- Testing
- bermekimab
- Where
- 33 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis, Hidradenitis Suppurativa (HS)
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and…
- Conditions
- Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
- Trial name
- NCT06946641
- Testing
- QLS12010
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Hidradenitis Suppurativa (HS)
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label…
- Trial name
- TibuSHIELD (NCT06993610)
- Testing
- Tibulizumab Dose A, Tibulizumab Dose B
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 247 people
- Sponsor
- Zura Bio Inc
Hidradenitis Suppurativa
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa
- Trial name
- HS2006 (NCT00795574)
- Testing
- infliximab
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- ARQ-MA-000260 (NCT07689188)
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Harrison Dermatology